Breakthrough Pain In Opioid-tolerant Patients Research Articles

194 Fentanyl buccal tablet (FBT) in the treatment of breakthrough pain in opioid-tolerant patients with chronic neuropathic pain: randomized, placebo-controlled study

194 Fentanyl buccal tablet (FBT) in the treatment of breakthrough pain in opioid-tolerant patients with chronic neuropathic pain: randomized, placebo-controlled study

A buccal fentanyl tablet has demonstrated considerable efficacy for breakthrough pain in opioid-tolerant patients with chronic low back pain,

A buccal fentanyl tablet has demonstrated considerable efficacy for breakthrough pain in opioid-tolerant patients with chronic low back pain,

(312/729): A randomized, placebo-controlled study of fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-tolerant patients with cancer

(312/729): A randomized, placebo-controlled study of fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-tolerant patients with cancer

Fentanyl Buccal Tablet in Breakthrough Pain in Opioid-Tolerant Patients with Cancer

Fentanyl Buccal Tablet in Breakthrough Pain in Opioid-Tolerant Patients with Cancer

Fentanyl Buccal Tablet

The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer. Fentanyl is rapidly absorbed from FBT across the buccal mucosa and into the bloodstream. Fentanyl is more rapidly absorbed and bioavailability is higher from FBT than from the oral transmucosal fentanyl citrate formulation. In a well designed phase III trial in opioid-tolerant patients with cancer, a single dose of FBT 100-800 microg provided clinically significant improvements in pain intensity from 15 to 60 minutes after the dose. Single FBT doses of 100-800 microg were generally well tolerated; the majority of adverse events were mild to moderate in nature and typical of those associated with opioids.

Fentanyl Buccal Tablet in Breakthrough Pain in Opioid-Tolerant Patients with Cancer

Fentanyl Buccal Tablet in Breakthrough Pain in Opioid-Tolerant Patients with Cancer

Opioids in non-cancer pain: Utilization of Oral Transmucosal Fentanyl Citrate (OTFC®) in chronic noncancer pain: A retrospective survey of 100 patients

Oral transmucosal fentanyl citrate (OTFC®; ACTIQ®) provides rapid and effective analgesia for breakthrough pain in opioid-tolerant patients with cancer and may provide a therapeutic option in patients with noncancer pain. OTFC is available in 6 dosage strengths (200-1600 mcg) to allow individualization of dosing; the appropriate dose is determined by titration. We evaluated the titration and usage patterns of OTFC in patients with chronic noncancer pain. We conducted a retrospective survey at 5 centers, reviewing medical charts from 100 noncancer pain patients who received OTFC (between June 1999 and May 2003). Data recorded at each of 3 clinic visits included OTFC dose at starting visit, after titration to successful dose (defined as 1 OTFC unit providing adequate pain relief with acceptable side effects), and follow-up (last) visit. The number of OTFC units/day, concomitant analgesics, and pain intensity scores (0-10 scale; available at 4/5 sites) were also recorded. Adverse events weren't systematically recorded. Of the 100 patients (mean age 47 years, 64% female), OTFC was being used in a variety of chronic noncancer pain conditions, the most common being back pain (36%), headache (17%), and complex regional pain syndrome (9%). The most common starting doses of OTFC were 400 mcg (41%) and 800 mcg (21%). After titration, the distribution (% of patients) of successful OTFC dosage strengths was: 200 mcg, 12%; 400 mcg, 39%; 600 mcg, 12%; 800 mcg, 24%; 1200 mcg, 8%; and 1600 mcg, 6%. At follow-up, 70% of patients had no change or a decrease in the OTFC dosage strength, and 74% of patients were using 1-4 OTFC units/day. The mean improvement in pain intensity scores from first to last visit was -1.5 (n=71; P<0.01). In this observational survey, OTFC was being used successfully to help manage a variety of chronic noncancer pain conditions.